BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 8, 2018

Primary Completion Date

November 13, 2020

Study Completion Date

November 13, 2020

Conditions
Cervical Cancer
Interventions
DRUG

Nivolumab induction

2 doses Nivolumab 240mg IV

DRUG

Cisplatin

40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.

RADIATION

Radiation

"Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field"

DRUG

Nivolumab with chemoradiation

Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.

DRUG

Nivolumab maintenance

Nivolumab 480 mg IV every 4 weeks for 2 years

Trial Locations (2)

02903

Rhode Island Hospital, Providence

02905

Women and Infants Hospital, Providence

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Rhode Island Hospital

OTHER

collaborator

The Miriam Hospital

OTHER

collaborator

Women and Infants Hospital of Rhode Island

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Brown University

OTHER